Clinical Outcomes in Early Breast Cancer with a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial

Joseph A. Sparano, Robert J. Gray, Della F. Makower, Kathy S. Albain, Thomas J. Saphner, Sunil S. Badve, Lynne I. Wagner, Virginia G. Kaklamani, Maccon M. Keane, Henry L. Gomez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Deborah L. Toppmeyer, Adam M. Brufsky, Matthew P. Goetz, Jeffrey L. Berenberg, Catalin Mahalcioiu, Christine Desbiens, Daniel F. HayesElizabeth C. Dees, Charles E. Geyer, John A. Olson, William C. Wood, Tracy Lively, Soonmyung Paik, Matthew J. Ellis, Jeffrey Abrams, George W. Sledge

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Fingerprint

Dive into the research topics of 'Clinical Outcomes in Early Breast Cancer with a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences